REGULATORY
PAFSC’s Second Committee Recommends Approval for Pfizer’s JAK Inhibitor Xeljanz, Others
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs, an advisory organ to the health minister, on March 13 reviewed and recommended approval for Pfizer Japan’s rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib citrate). The product, along with…
To read the full story
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





